Next Article in Journal
Metabolomics of Pigmented Rice Coproducts Applying Conventional or Deep Eutectic Extraction Solvents Reveal a Potential Antioxidant Source for Human Nutrition
Next Article in Special Issue
Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models
Previous Article in Journal
Metabolic Fingerprinting of Feces from Calves, Subjected to Gram-Negative Bacterial Endotoxin
Open AccessArticle

Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma

1
Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158, USA
2
Department of Neurological Surgery, Helen Diller Research Center, University of California, San Francisco, CA 94158, USA
3
Brain Tumor Research Center, University of California, San Francisco, CA 94158, USA
4
Arnie Charbonneau Cancer Institute and Hotchkiss Brain Institute, University of Calgary, Calgary, AB T2N 4N1, Canada
*
Author to whom correspondence should be addressed.
Academic Editor: Andre F. Martins
Metabolites 2021, 11(2), 109; https://doi.org/10.3390/metabo11020109
Received: 13 January 2021 / Revised: 9 February 2021 / Accepted: 10 February 2021 / Published: 13 February 2021
Approximately 80% of low-grade glioma (LGGs) harbor mutant isocitrate dehydrogenase 1/2 (IDH1/2) driver mutations leading to accumulation of the oncometabolite 2-hydroxyglutarate (2-HG). Thus, inhibition of mutant IDH is considered a potential therapeutic target. Several mutant IDH inhibitors are currently in clinical trials, including AG-881 and BAY-1436032. However, to date, early detection of response remains a challenge. In this study we used high resolution 1H magnetic resonance spectroscopy (1H-MRS) to identify early noninvasive MR (Magnetic Resonance)-detectable metabolic biomarkers of response to mutant IDH inhibition. In vivo 1H-MRS was performed on mice orthotopically-implanted with either genetically engineered (U87IDHmut) or patient-derived (BT257 and SF10417) mutant IDH1 cells. Treatment with either AG-881 or BAY-1436032 induced a significant reduction in 2-HG. Moreover, both inhibitors led to a significant early and sustained increase in glutamate and the sum of glutamate and glutamine (GLX) in all three models. A transient early increase in N-acetylaspartate (NAA) was also observed. Importantly, all models demonstrated enhanced animal survival following both treatments and the metabolic alterations were observed prior to any detectable differences in tumor volume between control and treated tumors. Our study therefore identifies potential translatable early metabolic biomarkers of drug delivery, mutant IDH inhibition and glioma response to treatment with emerging clinically relevant therapies. View Full-Text
Keywords: noninvasive metabolic biomarkers; mutant IDH inhibitor; glioma; 1H-MRS noninvasive metabolic biomarkers; mutant IDH inhibitor; glioma; 1H-MRS
Show Figures

Graphical abstract

MDPI and ACS Style

Radoul, M.; Hong, D.; Gillespie, A.M.; Najac, C.; Viswanath, P.; Pieper, R.O.; Costello, J.F.; Luchman, H.A.; Ronen, S.M. Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma. Metabolites 2021, 11, 109. https://doi.org/10.3390/metabo11020109

AMA Style

Radoul M, Hong D, Gillespie AM, Najac C, Viswanath P, Pieper RO, Costello JF, Luchman HA, Ronen SM. Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma. Metabolites. 2021; 11(2):109. https://doi.org/10.3390/metabo11020109

Chicago/Turabian Style

Radoul, Marina; Hong, Donghyun; Gillespie, Anne M.; Najac, Chloé; Viswanath, Pavithra; Pieper, Russell O.; Costello, Joseph F.; Luchman, Hema A.; Ronen, Sabrina M. 2021. "Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma" Metabolites 11, no. 2: 109. https://doi.org/10.3390/metabo11020109

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop